The Clinical and Parasitologic Follow-up of Trypanosoma cruzi-infected Children in a Nonendemic Country.
Adolescent
Chagas Disease
/ drug therapy
Child
Child, Preschool
Chronic Disease
Female
Follow-Up Studies
Humans
Infant
Infant, Newborn
Longitudinal Studies
Male
Nitroimidazoles
/ therapeutic use
Prospective Studies
Spain
/ epidemiology
Treatment Outcome
Trypanocidal Agents
/ therapeutic use
Trypanosoma cruzi
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
25
2
2020
medline:
7
4
2021
entrez:
25
2
2020
Statut:
ppublish
Résumé
Chagas disease has become a global health problem, with the pediatric population being especially vulnerable. Our aim was to describe the clinical-epidemiologic aspects of disease in this population, as well as tolerance and adherence to treatment and the subsequent evolution of the disease. A prospective study involving 949 children 0-14 years of age screened from 2007 to 2018. Diagnosis was performed by polymerase chain reaction and/or microhematocrit in <1-year-old children or serology in those ≥1 year of age. After diagnosis, children were examined for the clinical manifestation of Chagas disease and were treated with benznidazole. Treatment response was monitored by polymerase chain reaction and serology. Forty children were infected (4.2% of the population screened). Twelve children were diagnosed during the acute phase (≤1-year-old), 3 of whom were symptomatic, and 28 (4- to 14-year-olds) were in the chronic phase: 18 in the indeterminate phase and 10 presented cardiac and/or digestive involvement. Regarding treatment, 10 (25.6%) children had side effects (6 mild, 2 moderate and 2 severe reactions), leading to treatment interruption in 3 of them. No side effects were detected in ≤1-year-old children (P < 0.05). Cure was confirmed in 29.4% of the children during follow-up, and the age of the children at treatment (≤1 year) was clearly associated with the effectiveness of treatment (P < 0.05). Effectiveness and safety of treatment were optimum in ≤1-year-old children. Increased side effects, cardiac and/or digestive disorder incidence and lower treatment effectiveness were detected in older children, highlighting the need for early screening.
Sections du résumé
BACKGROUND
Chagas disease has become a global health problem, with the pediatric population being especially vulnerable. Our aim was to describe the clinical-epidemiologic aspects of disease in this population, as well as tolerance and adherence to treatment and the subsequent evolution of the disease.
METHODS
A prospective study involving 949 children 0-14 years of age screened from 2007 to 2018. Diagnosis was performed by polymerase chain reaction and/or microhematocrit in <1-year-old children or serology in those ≥1 year of age. After diagnosis, children were examined for the clinical manifestation of Chagas disease and were treated with benznidazole. Treatment response was monitored by polymerase chain reaction and serology.
RESULTS
Forty children were infected (4.2% of the population screened). Twelve children were diagnosed during the acute phase (≤1-year-old), 3 of whom were symptomatic, and 28 (4- to 14-year-olds) were in the chronic phase: 18 in the indeterminate phase and 10 presented cardiac and/or digestive involvement. Regarding treatment, 10 (25.6%) children had side effects (6 mild, 2 moderate and 2 severe reactions), leading to treatment interruption in 3 of them. No side effects were detected in ≤1-year-old children (P < 0.05). Cure was confirmed in 29.4% of the children during follow-up, and the age of the children at treatment (≤1 year) was clearly associated with the effectiveness of treatment (P < 0.05).
CONCLUSIONS
Effectiveness and safety of treatment were optimum in ≤1-year-old children. Increased side effects, cardiac and/or digestive disorder incidence and lower treatment effectiveness were detected in older children, highlighting the need for early screening.
Identifiants
pubmed: 32091491
doi: 10.1097/INF.0000000000002603
pii: 00006454-202006000-00005
doi:
Substances chimiques
Nitroimidazoles
0
Trypanocidal Agents
0
benzonidazole
YC42NRJ1ZD
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
494-499Références
Monge-Maillo B, López-Vélez R. Challenges in the management of Chagas disease in Latin-American migrants in Europe. Clin Microbiol Infect. 2017;23:290–295.
Soriano-Arandes A, Basile L, Ouaarab H, et al. Controlling congenital and paediatric Chagas disease through a community health approach with active surveillance and promotion of paediatric awareness. BMC Public Health. 2014;14:1201.
Wagner N, Jackson Y, Chappuis F, et al. Screening and management of children at risk for Chagas disease in nonendemic areas. Pediatr Infect Dis J. 2016;35:335–337.
Carlier Y, Torrico F, Sosa-Estani S, et al. Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women. PLoS Negl Trop Dis. 2011;5:e1250.
Messenger LA, Bern C. Congenital Chagas disease: current diagnostics, limitations and future perspectives. Curr Opin Infect Dis. 2018;31:415–421.
Bern C. UpToDate, Post TW. UpToDate, Post TWChagas disease: acute and congenital In: Trypanosoma Cruzi Infection. 2019.Waltham, MA.
Andrade AL, Martelli CM, Oliveira RM, et al. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg. 2004;71:594–597.
Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391:82–94.
Salazar-Schettino PM, Perera R, Ruiz-Hernandez AL, et al. Chagas disease as a cause of symptomatic chronic myocardiopathy in Mexican children. Pediatr Infect Dis J. 2009;28:1011–1013.
Simón M, Gil-Gallardo LJ, Asunción Iborra M, et al. An observational longitudinal study to evaluate tools and strategies available for the diagnosis of congenital Chagas disease in a non-endemic country. Acta Trop. 2019;199:105127.
World Health Organization Expert Committee on the Control of Chagas Disease (Brasilia, 20–28 November 2000) & World Health Organization. Control of Chagas disease: second report of the WHO expert committee. 2002. World Health Organization. Available at: https://apps.who.int/iris/handle/10665/42443.
Murcia L, Simón M, Carrilero B, et al. Treatment of infected women of childbearing age prevents congenital Trypanosoma cruzi infection by eliminating the parasitemia detected by PCR. J Infect Dis. 2017;215:1452–1458.
Requena-Méndez A, Albajar-Viñas P, Angheben A, et al. Chagas Disease COHEMI Working Group. Health policies to control Chagas disease transmission in European countries. PLoS Negl Trop Dis. 2014;8:e3245.
Sicuri E, Muñoz J, Pinazo MJ, et al. Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Trop. 2011;118:110–117.
Requena-Méndez A, Bussion S, Aldasoro E, et al. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis. Lancet Glob Health. 2017;5:e439–e447.
Messenger LA, Gilman RH, Verastegui M, et al. Toward improving early diagnosis of congenital Chagas disease in an endemic setting. Clin Infect Dis. 2017;65:268–275.
Colantonio LD, Prado N, Segura EL, et al. Electrocardiographic abnormalities and treatment with benznidazole among children with chronic infection by Trypanosoma cruzi: a retrospective cohort study. PLoS Negl Trop Dis. 2016;10:e0004651.
Sánchez-Montalvá A, Salvador F, Rodríguez-Palomares J, et al. Chagas cardiomyopathy: usefulness of EKG and echocardiogram in a non-endemic country. PLoS One. 2016;11:e0157597.
Bern C. Chagas’ disease. N Engl J Med. 2015;373:1882.
Altcheh J, Moscatelli G, Moroni S, et al. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics. 2011;127:e212–e218.
Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Negl Trop Dis. 2009;3:e488.
Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg. 1998;59:526–529.
Carrilero B, Murcia L, Martínez-Lage L, et al. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Rev Esp Quimioter. 2011;24:123–126.
Aldasoro E, Pinazo MJ, Oliveira I, et al. Arthritis and benznidazole: more closely related than we thought. Antimicrob Agents Chemother. 2015;59:727–729.
González-Ramos J, Noguera-Morel L, Tong HY, et al. Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. Br J Dermatol. 2016;175:604–607.
Viotti R, Alarcón de Noya B, Araujo-Jorge T, et al. Latin American Network for Chagas Disease, NHEPACHA. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58:635–639.
Blasco-Hernández T, García-San Miguel L, Navaza B, et al. Knowledge and experiences of Chagas disease in Bolivian women living in Spain: a qualitative study. Glob Health Action. 2016;9:30201.
Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724–734.
Murcia L, Carrilero B, Ferrer F, et al. Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result. Eur J Clin Microbiol Infect Dis. 2016;35:1819–1827.
Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother. 2003;52:441–449.
Rodriguez-Guerineau L, Posfay-Barbe KM, Monsonis-Cabedo M, et al. Pediatric Chagas disease in Europe: 45 cases from Spain and Switzerland. Pediatr Infect Dis J. 2014;33:458–462.
de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348:1407–1413.
Fabbro DL, Streiger ML, Arias ED, et al. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007;40:1–10.
Murcia L, Carrilero B, Muñoz MJ, et al. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas’ disease: a prospective study in a non-disease-endemic country. J Antimicrob Chemother. 2010;65:1759–1764.
Bianchi F, Cucunubá Z, Guhl F, et al. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia. PLoS Negl Trop Dis. 2015;9:e0003465.